Mesoblast (MESO) Operating Margin (2016 - 2023)
Mesoblast recorded quarterly Operating Margin of 1112.79% in Q2 2023, up 118.86% quarter-over-quarter from 5901.24% in Q1 2023, and up 423361.0% year-over-year from N/an in Q2 2022.
Mesoblast's Operating Margin history runs 8 years deep, the most recent figure standing at 1112.79% for Q2 2023.
- In Q2 2023, Operating Margin rose 423361.0% year-over-year to 1112.79%; the TTM figure through Mar 2023 stood at 17170.99% (down 7369576.0% YoY), while the FY2025 annual figure was 360.79%, changed N/A from the prior year.
- Operating Margin came in at 1112.79% for Q2 2023 at Mesoblast, up from 5901.24% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 349433.42% in Q2 2021 to a low of 79504.19% in Q1 2021.
- A 5-year average of 2992.46% and a median of 12870.17% in 2019 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin surged 34112451 bps in 2021 and tumbled 35255424 bps in 2022, its largest moves.
- Mesoblast's Operating Margin stood at 37321.23% in 2019, then jumped by 101 bps to 447.52% in 2020, then tumbled by 9278 bps to 41074.56% in 2021, then slipped by 2 bps to 41919.39% in 2022, then surged by 103 bps to 1112.79% in 2023.
- According to Business Quant data, Operating Margin over the past three periods registered 1112.79%, 5901.24%, and 41919.39% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1,112.79% |
| Mar 31, 2023 | -5,901.24% |
| Dec 31, 2022 | -41,919.39% |
| Sep 30, 2022 | -20,010.74% |
| Jun 30, 2022 | -3,120.82% |
| Mar 31, 2022 | 232.27% |
| Dec 31, 2021 | -41,074.56% |
| Sep 30, 2021 | -42,137.41% |
| Jun 30, 2021 | 349,433.42% |
| Mar 31, 2021 | -79,504.19% |
| Dec 31, 2020 | 447.52% |
| Sep 30, 2020 | 663.52% |
| Jun 30, 2020 | 8,308.90% |
| Mar 31, 2020 | -53,957.57% |
| Dec 31, 2019 | -37,321.23% |
| Sep 30, 2019 | -19,839.10% |
| Jun 30, 2019 | 556.89% |
| Mar 31, 2019 | -69,833.30% |
| Dec 31, 2018 | -58,452.26% |
| Sep 30, 2018 | -58,792.84% |
| Jun 30, 2018 | 1,006.94% |
| Mar 31, 2018 | -78,264.18% |
| Dec 31, 2017 | -23,533.42% |
| Sep 30, 2017 | 1,334.33% |
| Jun 30, 2017 | 2,712.90% |
| Mar 31, 2017 | 1,220.75% |
| Dec 31, 2016 | 2,698.85% |
| Sep 30, 2016 | 5,012.39% |
| Jun 30, 2016 | 124.83% |
| Mar 31, 2016 | 211.51% |